Sana Biotechnology is a biotechnology company developing engineered cell medicines. Its programs target blood cancers, autoimmune diseases, and type 1 diabetes using hypoimmune and cell engineering platforms.
Sana Biotechnology stock gapped up over 13% on Tuesday after beating Q1 earnings estimates, continuing a Monday rally. Analysts reaffirmed a Moderate Buy consensus with a $9.50 target, as institutional ownership remains high at 88%.
Sana Biotechnology named Brian Piper executive vice president and CFO as it advanced SC451 and SG293. The company reported a fourth-quarter loss of $59 million and cash of $138 million.
Sana Biotechnology appointed Brian Piper as Executive Vice President and Chief Financial Officer on February 17, 2026. Piper brings over 25 years of biopharmaceutical financial expertise to the cell and gene therapy company.
Sana Biotechnology received an analyst downgrade as the FDA increases regulatory scrutiny on gene therapies, raising questions about the company's cash runway and clinical progress ahead of its mid-March 2026 quarterly update.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06294236 |
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM) |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06285422 |
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06239636 |
First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes |
RECRUITING | EARLY_PHASE1 |
| NCT05878184 |
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT03047369 |
The Myelin Disorders Biorepository Project |
RECRUITING |
